These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30507463)

  • 21. Interferon-alpha for chronic hepatitis C: reducing the uncertainties.
    Koff RS
    Ann Intern Med; 1997 Nov; 127(10):918-20. PubMed ID: 9382371
    [No Abstract]   [Full Text] [Related]  

  • 22. Why We Should Be Willing to Pay for Hepatitis C Treatment.
    Chhatwal J; Chen Q; Kanwal F
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1711-3. PubMed ID: 26091736
    [No Abstract]   [Full Text] [Related]  

  • 23. Sticker shock and the price of new therapies for hepatitis C: is it worth it?
    Reau NS; Jensen DM
    Hepatology; 2014 Apr; 59(4):1246-9. PubMed ID: 24493069
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A world without hepatitis C.
    Ryder S; Dillon J
    Health Serv J; 2014 May; 124(6397):21-3. PubMed ID: 25033511
    [No Abstract]   [Full Text] [Related]  

  • 26. Combination therapy in naive patients with chronic hepatitis C: more value for the money.
    Koff RS
    J Hepatol; 2000 Oct; 33(4):664-6. PubMed ID: 11059875
    [No Abstract]   [Full Text] [Related]  

  • 27. [Economic evaluation of combined therapy in chronic hepatitis C].
    Casado MA; Buti M; Fosbrook L; Esteban R
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():57-62. PubMed ID: 11968346
    [No Abstract]   [Full Text] [Related]  

  • 28. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Special report: cost-effectiveness studies of new hepatitis C treatments.
    Mark DH;
    Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188
    [No Abstract]   [Full Text] [Related]  

  • 30. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.
    He T; Lopez-Olivo MA; Hur C; Chhatwal J
    Aliment Pharmacol Ther; 2017 Oct; 46(8):711-721. PubMed ID: 28836278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
    Deuffic-Burban S; Obach D; Canva V; Pol S; Roudot-Thoraval F; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Viral Hepat; 2016 Oct; 23(10):767-79. PubMed ID: 27144512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
    Suenaga R; Suka M; Hirao T; Hidaka I; Sakaida I; Ishida H
    PLoS One; 2021; 16(4):e0248748. PubMed ID: 33793594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
    Ciaccio A; Cortesi PA; Bellelli G; Rota M; Conti S; Okolicsanyi S; Rota M; Cesana G; Mantovani LG; Annoni G; Strazzabosco M
    Liver Int; 2017 Jul; 37(7):982-994. PubMed ID: 27943549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cost-effectiveness of antiviral therapy for chronic hepatitis C patients in prevention of hepatocellular cancer ].
    Yoshida H; Tateishi R; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):511-4. PubMed ID: 15359852
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of hepatitis C: momentum still needed.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2018 May; 3(5):289. PubMed ID: 29644967
    [No Abstract]   [Full Text] [Related]  

  • 36. Does patient cost sharing for HCV drugs make sense?
    Lakdawalla DN; Linthicum MT; Vanderpuye-Orgle J
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP188-90. PubMed ID: 27266947
    [No Abstract]   [Full Text] [Related]  

  • 37. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong.
    Li X; Chan NS; Tam AW; Hung IFN; Chan EW
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1801-1809. PubMed ID: 28516201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market.
    Mance D; Mance D; Vitezić D
    Croat Med J; 2016 Dec; 57(6):582-590. PubMed ID: 28051283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.
    Bickerstaff C
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):787-800. PubMed ID: 26289734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.